한글목차

허혈성 뇌졸중의 동향과 예측

세계의 허혈성 뇌졸중 시장은 2024-2030년의 CAGR이 7.5%로, 2030년까지 추정 71억 8,000만 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 사람들 사이에서 건강 의식의 향상, 세계의 당뇨병률 상승, 담배 사용자의 증가입니다. 세계의 허혈성 뇌졸중 시장은 CT, MRI, 경동맥 초음파 검사, 뇌혈관 촬영의 각 시장에서의 비즈니스 기회에 의해 미래가 유망시되고 있습니다.

부문별 허혈성 뇌졸중

세계의 허혈성 뇌졸중 진단, 약제 클래스별, 지역별 예측을 제공합니다.

허혈성 뇌졸중 관련 기업 리스트

시장에 참여하고 있는 기업은 제공하는 제품 품질에 기반해 경쟁하고 있습니다. 이 시장의 주요 기업은 제조 시설의 확대, 연구개발 투자, 인프라 개척, 밸류체인 전체에서 통합 기회의 활용에 주력하고 있습니다. 이 전략에 의해 허혈성 뇌졸중 기업은 수요의 증가에 대응하고, 경쟁력을 확보하고, 혁신적인 제품과 기술을 개발하고, 제조 비용을 삭감하고, 고객 기반을 확대하고 있습니다. 본 리포트에서 소개하는 허혈성 뇌졸중 기업은 아래와 같습니다.

• Abbott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic

허혈성 뇌졸중 사노피

• Lucintel의 예측에서는 항혈소판약이 혈전 형성을 예방하고, 이후 뇌졸중의 리스크를 최소한으로 억제하기 위해 허혈성 뇌졸중의 제일 선택약으로 사용되므로 예측 기간 중에도 최대 부문으로 유지됩니다.
• CT는 소요 시간이 짧고, 뇌 해부학적 구조를 상세히 볼 수 있으므로 최대 부문으로 유지될 것으로 생각됩니다.
• 예측 기간 중 북미가 최대 부문으로 유지되는 것은 이 지역에서 정부의 호의적 구상과 지속적 기술 진보에 의한 것입니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품에는 어떤 것이 있으며, 재료 및 제품의 대체에 의한 시장 점유율 저하의 위협은 어느 정도 있는가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 허혈성 뇌졸중 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 허혈성 뇌졸중 시장의 동향(2018-2023년)과 예측(2024-2030년)
• 진단별 세계의 허혈성 뇌졸중 시장
  • CT
  • MRI
  • 경동맥 초음파 검사
  • 뇌혈관조영
• 약제 클래스별 세계의 허혈성 뇌졸중 시장
  • 조직 플라스미노겐 활성화인자
  • 항응고제
  • 항혈소판
  • 강압제

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 허혈성 뇌졸중 시장
• 북미의 허혈성 뇌졸중 시장
• 유럽의 허혈성 뇌졸중 시장
• 아시아태평양 허혈성 뇌졸중 시장
• 기타 지역의 허혈성 뇌졸중 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 진단별 세계의 허혈성 뇌졸중 시장의 성장 기회
  • 약제 클래스별 세계의 허혈성 뇌졸중 시장의 성장 기회
  • 지역별 세계의 허혈성 뇌졸중 시장의 성장 기회
• 세계의 허혈성 뇌졸중 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 허혈성 뇌졸중 시장의 능력 확대
  • 세계의 허혈성 뇌졸중 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Abott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.

영문목차

Ischemic Stroke Trends and Forecast

The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

A more than 150-page report is developed to help in your business decisions.

Ischemic Stroke by Segment

The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.

Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

• CT
• MRI
• Carotid Ultrasounds
• Cerebral Angiography

Ischemic Stroke Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Tissue Plasminogen Activator
• Anticoagulant
• Antiplatelet
• Antihypertensive

Ischemic Stroke Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Ischemic Stroke Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-

• Abbott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic

Ischemic Stroke Sanofi

• Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

• CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.

• North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Features of the Global Ischemic Stroke Market

• Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).

• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

• Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region. in terms of value ($B).

• Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

• Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and region.s for the ischemic stroke market.

• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.

• Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the ischemic stroke market size?

Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.

Q.2. What is the growth forecast for ischemic stroke market?

Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the ischemic stroke market?

Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

Q.4. What are the major segments for ischemic stroke market?

Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.

Q.5. Who are the key Ischemic Stroke Market companies?

Answer: Some of the key ischemic stroke companies are as follows:

• Abbott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.

Q.6. Which ischemic stroke market segment will be the largest in future?

Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

Q.7. In ischemic stroke market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ischemic Stroke Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Ischemic Stroke Market by Diagnosis
  • 3.3.1: CT
  • 3.3.2: MRI
  • 3.3.3: Carotid Ultrasounds
  • 3.3.4: Cerebral Angiography
• 3.4: Global Ischemic Stroke Market by Drug Class
  • 3.4.1: Tissue Plasminogen Activator
  • 3.4.2: Anticoagulant
  • 3.4.3: Antiplatelet
  • 3.4.4: Antihypertensive

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Ischemic Stroke Market by Region
• 4.2: North American Ischemic Stroke Market
  • 4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.3: European Ischemic Stroke Market
  • 4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.4: APAC Ischemic Stroke Market
  • 4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.5: ROW Ischemic Stroke Market
  • 4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
  • 6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
  • 6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
• 6.2: Emerging Trends in the Global Ischemic Stroke Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abott Laboratories
• 7.2: Bayer
• 7.3: Boehringer Ingelheim
• 7.4: Boston Scientific Corporation
• 7.5: Cordis Corporation
• 7.6: Covidien
• 7.7: GE Healthcare
• 7.8: Genentech
• 7.9: Johnson & Johnson
• 7.10: Koninklijke Philips N.V.